Baxalta Inc (BXLT) [Rocket]

In millions, except per share items	Dec-31-15	Dec-31-14	Dec-31-13
	10-K	10-K	10-K
Revenues:
Hemophilia	2,840	2,984	2,786
Immunoglobulin Therapies	1,750	1,677	1,616
Inhibitor Therapies	787	744	651
Bio Therapeutics	684	547	502
Oncology	87
Total revenues	6,148	5,952	5,555
Revenue growth [+]	3.3%	7.1%
Hemophilia	-4.8%	7.1%
Immunoglobulin Therapies	4.4%	3.8%
Inhibitor Therapies	5.8%	14.3%
Bio Therapeutics	25.0%	9.0%
Cost of goods sold	2,386	2,443	2,329
Gross profit	3,762	3,509	3,226
Gross margin	61.2%	59.0%	58.1%
Selling, general and administrative	1,442	1,053	1,017
Research and development	1,176	820	595
Other operating expenses	-1	124	-6
EBITDA [+]	1,402	1,718	1,804
EBITDA growth	-18.4%	-4.8%
EBITDA margin	22.8%	28.9%	32.5%
Depreciation	204	190	184
EBITA	1,198	1,528	1,620
EBITA margin	19.5%	25.7%	29.2%
Amortization of intangibles	53	16
EBIT [+]	1,145	1,512	1,620
EBIT growth	-24.3%	-6.7%
EBIT margin	18.6%	25.4%	29.2%
Non-recurring items	97	-124
Interest expense, net [+]	-48	-19	-23
Interest expense	95
Interest income	48	19	23
Other income (expense), net	197	-123	-30
Pre-tax income	1,198	1,532	1,613
Income taxes	270	346	325
Tax rate	22.5%	22.6%	20.1%
Earnings from continuing ops	928	1,186	1,288
Earnings from discontinued ops	28	551
Net income	956	1,737	1,288
Net margin	15.5%	29.2%	23.2%

Basic EPS [+]	$1.37	$1.75	$1.91
Growth	-21.9%	-7.9%
Diluted EPS [+]	$1.36	$1.74	$1.89
Growth	-22.0%	-7.9%

Dividends per share	$0.14

Shares outstanding (basic) [+]	677	676	676
Growth	0.1%	0.0%
Shares outstanding (diluted) [+]	683	681	681
Growth	0.3%	0.0%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.